Should I Buy CCRN? CCRN 2026 Analysis

Should You Buy Cross Country Healthcare Inc (CCRN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

8.690

1 Day change

-0.57%

52 Week Range

18.280

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: no proprietary buy signals, weak recent fundamentals, and the chart is sitting in a chop zone near resistance.
Upside exists toward $10–$11 (Street PT cluster) if execution/M&A narrative improves, but the current setup doesn’t offer a high-conviction immediate edge.
Preferred stance: hold off until price either (a) reclaims and holds above ~$9.35–$9.56 with momentum, or (b) revisits ~$8.62 support with stabilization for a cleaner risk/reward entry.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Pre-market price ~$9.10 is just above the pivot (8.983) and below first resistance (R1 9.342): near-term range-bound behavior likely.
MACD histogram is above zero (0.0645) but positively contracting: upside momentum exists but is fading.
RSI(6) ~46.8 (neutral): no oversold/overbought edge.
Moving averages converging: typically indicates consolidation rather than a trending move.
Key levels: Support S1 8.624 then S2 8.402; Resistance R1 9.342 then R2 9.564. A clean break above R1/R2 would improve the buy case.
Pattern-based projection provided: slight negative bias over the next week (-2.64%), modestly positive over the next month (+2.75%), implying choppy near-term trade.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Open interest put/call at 0.64 suggests a call-leaning positioning (mildly bullish).
Volume put/call at 0.92 is close to neutral (slight put tilt on the day), so sentiment is not decisively bullish.
Implied volatility (30D) ~219.9% with IV percentile 89.6 / IV rank 78.6: options are priced for large moves; this often reflects uncertainty and can coincide with whipsaws.
Today’s option activity is elevated vs average (though absolute volume is small), consistent with heightened speculative interest rather than steady conviction.

Technical Summary

Sell

Buy

Positive Catalysts

- Strategic pivot toward a tech-enabled staffing model could re-rate the stock if execution is credible.
- CEO/co-founder Kevin Clark’s return is viewed positively by at least one firm as an execution catalyst.
- Clean balance sheet and liquidity (~$119M noted by Wedbush) plus share repurchase intent can support downside.
- $20M merger termination fee and potential for renewed M&A interest if valuation remains compressed.
- Some analyst commentary suggests early signs of stabilization in healthcare staffing.

Neutral/Negative Catalysts

- Latest quarter shows sharp deterioration (revenue down ~20.7% YoY; EPS -0.15; net loss), which typically caps multiple expansion.
- Failed Aya merger removed a clear takeout floor; the stock is now more dependent on operational turnaround.
- Very high implied volatility implies the market expects big swings; near-term direction is less reliable.
- No fresh news in the last week to act as an immediate upside catalyst.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $250.1M, -20.65% YoY (clear contraction in demand/pricing environment).
Net income: -$4.77M (down -286.85% YoY, turning/remaining loss-making).
EPS: -0.15, -287.5% YoY.
Gross margin: 18.73%, down ~1.06% YoY (margin pressure persists).
Overall: fundamentals are trending down, so the buy case is primarily turnaround/strategic pivot rather than current earnings strength.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent Street tone is mixed but cautious: several Holds/Neutrals with price targets reset lower after the deal termination.
Wedbush (2026-02-03): initiated Neutral, PT $11, citing inflection potential from tech pivot, liquidity, CEO return, and compressed valuation.
Truist (2025-12-16): Hold, PT cut to $10 (deal-related target reset).
UBS (2025-12-09): Neutral, PT cut to $9.
Jefferies (2025-12-04): Hold, PT $8.65; noted breakup fee and buyback intent.
Citizens JMP (2025-12-04): upgraded to Outperform, PT $11; liked risk/reward at depressed levels and potential industry stabilization.
Wall Street pros: balance sheet strength, buybacks, pivot/M&A optionality. Cons: earnings/revenue decline and limited near-term visibility.

8 Analyst Rating

Wall Street analysts forecast CCRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCRN is 9.66 USD with a low forecast of 8.65 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

7 Hold

0 Sell

Hold

Current: 8.740

Low

8.65

Averages

9.66

High

Current: 8.740

Low

8.65

Averages

9.66

High

Wedbush

Neutral

initiated

$11

AI Analysis

2026-02-03

New

Reason

Wedbush

Price Target

$11

AI Analysis

2026-02-03

New

initiated

Neutral

Reason

Wedbush initiated coverage of Cross Country Healthcare with a Neutral rating and $11 price target. The firm says the company stands at a pivotal inflection point following the failed Aya Healthcare merger, with the combination of a recently announced strategic pivot to become a tech-enabled staffing provider, a debtfree balance sheet with $119M liquidity enabling strategic investments, co-founder Kevin Clark's return as CEO bringing proven technology platform development expertise, and compressed valuation multiples creating potential for material upside if the company successfully executes its technology-led transformation or attracts renewed acquisition interest at improved valuations.

Truist

Hold

downgrade

$10

2025-12-16

Reason

Truist

Price Target

$10

2025-12-16

downgrade

Hold

Reason

Truist lowered the firm's price target on Cross Country Healthcare to $10 from $18.61 and keeps a Hold rating on the shares. The firm's private price target was based on the proposed deal with Aya Healthcare, and the new price target reflects its evaluation of the business going forward, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CCRN

Unlock Now

CCRN Should I Buy

CCRN Should I Buy

Should You Buy Cross Country Healthcare Inc (CCRN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch